European Society for Medical Oncology Cancer Conference

February 09, 2004

YOU ARE INVITED...
to report on one of Europe's most important cancer conferences

29th ESMO Congress
Vienna, Austria
29 October-2 November 2004
(Austria Center Vienna)

The 29th ESMO Congress
the biennial conference of the European Society for Medical Oncology

More than 7,000 physicians and scientists will attend over 500 presentations on the latest developments concerning the diagnosis and treatment of cancer, progress in research, and promising new technologies.

International cancer specialists will review progress on important topics such as advances in breast cancer, colorectal cancer, leukaemia, lung cancer, lymphoma, new therapies, pharmacology, prostate cancer, palliative and supportive care, health services, and public health, just to name a few. New treatments involving molecular targets, and combined treatments requiring multidisciplinary approaches will be presented, along with state-of-the-art oncology at its finest.

Some other special features of the Congress:
  • The first ESMO-Developing Countries Joint Symposium will address disparities of cancer treatment on a global level.
  • A third ESMO Patient Seminar has been organised to enable patients to meet oncologists on an international scale, and to provide a forum for the discussion of the treatment of cancer.
  • A Session on ESMO Minimum Clinical Recommendations will update current ESMO guidelines on clinical practice for various tumour types.
  • Oncology Highlights of the most important advances in cancer treatment in 2004.

    Assisting you in Vienna...
    A Press Center will provide you with information, resources, and expert opinion. Press Conferences will be held, highlighting the most important topics, and you will have access to all the scientific sessions.

    Free Media Registration is granted at the Congress to all bona fide media representatives.

    A Media Registration Form, details about the Congress Program, and hotel accommodation will be available on the ESMO Web site at: www.esmo.org in March 2004.

    If you have any questions, please contact in English:
    Gracemarie Bricalli, ESMO Communication Manager
    tel. 41-091-973-19-11, fax 41-091-973-19-12, gracemarie@esmo.org
    -end-


    European Society for Medical Oncology

    Related Breast Cancer Articles from Brightsurf:

    Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
    The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

    Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
    New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

    Partial breast irradiation effective treatment option for low-risk breast cancer
    Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

    Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
    Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

    More clues revealed in link between normal breast changes and invasive breast cancer
    A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

    Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
    A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

    Computers equal radiologists in assessing breast density and associated breast cancer risk
    Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

    Blood test can effectively rule out breast cancer, regardless of breast density
    A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

    Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
    Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

    Young breast cancer patients undergoing breast conserving surgery see improved prognosis
    A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

    Read More: Breast Cancer News and Breast Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.